Medical guideline

首页肿瘤学指南检索结果

检索结果

按发表年份

共搜索到12条与GIST有关的结果

An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline: Consolidation Or Maintenance Systemic Therapy for Newly Diagnosed Stage Ii, Iii, Or Iv Epithelial Ovary, Fallopian Tube, Or Primary Peritoneal Carcinoma

2021年发布于 Current Oncology 28卷第2期 所属人体系统：其他 | 腹膜肿瘤

Ontario Health (Cancer Care Ontario)

Objective: to Provide Recommendations on Systemic Therapy Options in Consolidation Or Maintenance Therapy for Women with Newly Diagnosed Stage II III Or IV Epithelial Ovary Fallopian Tube Or Primary Peritoneal Carcinoma Including All Histological Types. Methods: Consistent with the Program in Evidence-based Program's Standardized Approach MEDLINE EMBASE PubMed Cochrane Library and PROSPERO (the International Prospective Register of Systematic Reviews) Databases and Four Relevant Conferences Were Systematically Searched. the Working Group Drafted Recommendations and Revised Them Based on the Comments from Internal and External Reviewers. Results: We Have One Recommendation for Consolidation Therapy and Eight Recommendations for Maintenance Therapy. Overall Consolidation Therapy with Chemotherapy Should Not Be Recommended in the Target Population. for Maintenance Therapy We Recommended Olaparib (Recommendation) Niraparib (Weak Recommendation) Veliparib (Weak Recommendation) and Bevacizumab (Weak Recommendation) for Certain Patients with Newly Diagnosed Stage III-IV Epithelial Ovarian Fallopian Tube Or Primary Peritoneal Carcinoma Respectively. We Do Not Recommend Some Agents as Maintenance Therapy in Four Recommendations. We Are Unable to Specify the Patient Population by Histological Types for Different Maintenance Therapy Recommendations. When New Evidence That Can Impact the Recommendations Is Available the Recommendations Will Be Updated as Soon as Possible.
指南简介 原文链接
Gastrointestinal Stromal Tumors (GIST)

2021年发布于 National Comprehensive Cancer Network 卷第期 所属人体系统：消化 | 胃肠道肿瘤

National Comprehensive Cancer Network

Gastrointestinal Stromal Tumors (GIST) treatment mutation Testing surgery systemic Therapy imaging
指南简介 原文链接
An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline: Consolidation Or Maintenance Systemic Therapy for Newly Diagnosed Stage Ii, Iii, Or Iv Epithelial Ovary, Fallopian Tube, Or Primary Peritoneal Carcinoma

2021年发布于 Current Oncology 28卷第2期 所属人体系统：生殖 | 输卵管癌

Ontario Health (Cancer Care Ontario)

Objective: to Provide Recommendations on Systemic Therapy Options in Consolidation Or Maintenance Therapy for Women with Newly Diagnosed Stage II III Or IV Epithelial Ovary Fallopian Tube Or Primary Peritoneal Carcinoma Including All Histological Types. Methods: Consistent with the Program in Evidence-based Program's Standardized Approach MEDLINE EMBASE PubMed Cochrane Library and PROSPERO (the International Prospective Register of Systematic Reviews) Databases and Four Relevant Conferences Were Systematically Searched. the Working Group Drafted Recommendations and Revised Them Based on the Comments from Internal and External Reviewers. Results: We Have One Recommendation for Consolidation Therapy and Eight Recommendations for Maintenance Therapy. Overall Consolidation Therapy with Chemotherapy Should Not Be Recommended in the Target Population. for Maintenance Therapy We Recommended Olaparib (Recommendation) Niraparib (Weak Recommendation) Veliparib (Weak Recommendation) and Bevacizumab (Weak Recommendation) for Certain Patients with Newly Diagnosed Stage III-IV Epithelial Ovarian Fallopian Tube Or Primary Peritoneal Carcinoma Respectively. We Do Not Recommend Some Agents as Maintenance Therapy in Four Recommendations. We Are Unable to Specify the Patient Population by Histological Types for Different Maintenance Therapy Recommendations. When New Evidence That Can Impact the Recommendations Is Available the Recommendations Will Be Updated as Soon as Possible.
指南简介 原文链接
An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline: Consolidation Or Maintenance Systemic Therapy for Newly Diagnosed Stage Ii, Iii, Or Iv Epithelial Ovary, Fallopian Tube, Or Primary Peritoneal Carcinoma

2021年发布于 Current Oncology 28卷第2期 所属人体系统：生殖 | 卵巢肿瘤

Ontario Health (Cancer Care Ontario)

Objective: to Provide Recommendations on Systemic Therapy Options in Consolidation Or Maintenance Therapy for Women with Newly Diagnosed Stage II III Or IV Epithelial Ovary Fallopian Tube Or Primary Peritoneal Carcinoma Including All Histological Types. Methods: Consistent with the Program in Evidence-based Program's Standardized Approach MEDLINE EMBASE PubMed Cochrane Library and PROSPERO (the International Prospective Register of Systematic Reviews) Databases and Four Relevant Conferences Were Systematically Searched. the Working Group Drafted Recommendations and Revised Them Based on the Comments from Internal and External Reviewers. Results: We Have One Recommendation for Consolidation Therapy and Eight Recommendations for Maintenance Therapy. Overall Consolidation Therapy with Chemotherapy Should Not Be Recommended in the Target Population. for Maintenance Therapy We Recommended Olaparib (Recommendation) Niraparib (Weak Recommendation) Veliparib (Weak Recommendation) and Bevacizumab (Weak Recommendation) for Certain Patients with Newly Diagnosed Stage III-IV Epithelial Ovarian Fallopian Tube Or Primary Peritoneal Carcinoma Respectively. We Do Not Recommend Some Agents as Maintenance Therapy in Four Recommendations. We Are Unable to Specify the Patient Population by Histological Types for Different Maintenance Therapy Recommendations. When New Evidence That Can Impact the Recommendations Is Available the Recommendations Will Be Updated as Soon as Possible.
指南简介 原文链接
Rationale of the Rare Cancer List: a Consensus Paper from the Joint Action on Rare Cancers (JARC) of the European Union (EU)

2020年发布于 ESMO Open 5卷第2期 所属人体系统：其他 | 罕见癌症

Joint Action on Rare Cancers

Cancer Registries Incidence Prevalence Rare Cancers.
指南简介 原文链接
ESUR/ESUI Consensus Statements on Multi-parametric MRI for the Detection of Clinically Significant Prostate Cancer: Quality Requirements for Image Acquisition, Interpretation and Radiologists' Training

2020年发布于 European Radiology 30卷第10期 所属人体系统：生殖 | 前列腺肿瘤

European Society of Urogenital Radiology EAU Section of Urologic Imaging

Multi-parametric MRI in the Diagnostic Pathway of Prostate Cancer Has a Well-established Upfront Role in the Recently Updated European Association of Urology Guideline and American Urological Association Recommendations. • Suboptimal Image Acquisition and Reporting at an Individual Level Will Result in Clinicians Losing Confidence in the Technique and Returning to the (non-MRI) Systematic Biopsy Pathway. Therefore It Is Crucial to Establish Quality Criteria for the Acquisition and Reporting of MpMRI. • to Ensure High-quality Prostate MRI Experts Consider Checking and Reporting of Image Quality Mandatory. Prostate Radiologists Must Attend Theoretical and Hands-on Courses Followed by Supervised Education and Must Perform Regular Self- and External Performance Assessments.
指南简介 原文链接
A Canadian Guideline on the Use of Next-generation Sequencing in Oncology

2019年发布于 Curr Oncol 26卷第2期 所属人体系统：其他 | 基因测序

无

Next-generation Sequencing Guidelines Molecular Genomics Oncologists Pathology Sequencing Somatic Variants.
指南简介 原文链接
Defining and Listing Very Rare Cancers of Paediatric Age: Consensus of the Joint Action on Rare Cancers in Cooperation with the European Cooperative Study Group for Pediatric Rare Tumors

2019年发布于 Eur J Cancer 110卷第期 所属人体系统：其他 | 罕见癌症

European Union Joint Action on Rare Cancers

Cancer Registries Consensus Incidence Very Rare Paediatric Cancers
指南简介 原文链接
Gastrointestinal Stromal Tumours (GISTs): French Intergroup Clinical Practice Guidelines for Diagnosis, Treatments and Follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO)

2019年发布于 Dig Liver Dis 51卷第9期 所属人体系统：消化 | 胃肠道肿瘤

Fédération Francophone De Cancérologie Digestive Fédération Nationale De Centres De Lutte Contre Les Cancers Groupe Coopérateur Multidisciplinaire En Oncologie Société Française De Chirurgie Digestive Société Française De Radiothérapie Oncologique Société Française D’Endoscopie Digestive Société Nationale Française De Gastroentérologie

Diagnosis Follow-up French Clinical Practice Guidelines GIST Prognosis Surgery Tyrosine Kinase Inhibitors
指南简介 原文链接
Nutritional Aspect of Cancer Care in Medical Oncology Patients

2019年发布于 Clin Ther 41卷第11期 所属人体系统：其他 | 康复营养

Turkey Medical Oncology Active Nutrition Platform

Cancer Cachexia Cancer Patients Medical Oncologist's Perspective Nutritional Screening Nutritional Support Treatment
指南简介 原文链接
German S3 Guideline for Renal Cell Carcinoma : Presentation and Discussion of Essential Aspects for the Radiation Oncologist

2018年发布于 Strahlenther Onkol 194卷第1期 所属人体系统：泌尿 | 肾癌

无

Purpose: We Aim to Introduce and Discuss the Statements and Recommendations of the German S3 Guideline on Renal Cell Cancer for Daily Practice of Radiation Oncologists Methods: This Report Comprises Indication Treatment Decision Dose Prescription and Current Literature Including Treatment of Oligometastatic Disease Results: According to Different Stages of the Disease and the Structure of the Guideline We Focus on Five Treatment Situations and Recommendations for Decision Making: (1) Neo-/adjuvant Treatment Before Or after Nephrectomy: No Indication for Radiotherapy (2) Small Renal Mass: Stereotactic Ablative Radiotherapy Is Currently Seen as Experimental Option due to Small Patient Numbers Reported in the Literature However Local Tumor Control Achieved by SBRT Appears Favourable with >90% at 2 Years (3) Oligometastasis: Radiation Treatment with Higher Local Doses Or Stereotactic Treatment Is Possible after Interdisciplinary Discussion Indications for Palliative (4) and Symptomatic Treatment (5) Are Not Different Compared to Other Tumor Entities Conclusion: Currently There Is No Evidence-based Indication for Radiation Treatment in the Primary Setting (adjuvant/neoadjuvant Or Definitive) of Renal Cell Cancer in the Future Stereotactic Radiotherapy Should Have a Stronger Role in the Treatment of Medically Inoperable Patients with Primary Renal Cell Cancer and Especially in the Setting of Oligometastasis
指南简介 原文链接
Molecular Analyses in the Diagnosis, Prognosis, and Selection of Therapy in Non-GIST Soft Tissue Sarcomas

2018年 所属人体系统：运动 | 软组织肿瘤

McMaster University

Non-GIST Soft Tissue Sarcomas Molecular Analyses Diagnosis prognosis Treatment
指南简介 原文链接

人体系统

共搜索到12条 与GIST有关的结果

2021年 发布于 Current Oncology 28卷 第2期 所属人体系统： 其他 | 腹膜肿瘤

Ontario Health (Cancer Care Ontario)

2021年 发布于 National Comprehensive Cancer Network 卷 第期 所属人体系统： 消化 | 胃肠道肿瘤

National Comprehensive Cancer Network

2021年 发布于 Current Oncology 28卷 第2期 所属人体系统： 生殖 | 输卵管癌

Ontario Health (Cancer Care Ontario)

2021年 发布于 Current Oncology 28卷 第2期 所属人体系统： 生殖 | 卵巢肿瘤

Ontario Health (Cancer Care Ontario)

2020年 发布于 ESMO Open 5卷 第2期 所属人体系统： 其他 | 罕见癌症

Joint Action on Rare Cancers

2020年 发布于 European Radiology 30卷 第10期 所属人体系统： 生殖 | 前列腺肿瘤

European Society of Urogenital Radiology EAU Section of Urologic Imaging

2019年 发布于 Curr Oncol 26卷 第2期 所属人体系统： 其他 | 基因测序

无

2019年 发布于 Eur J Cancer 110卷 第期 所属人体系统： 其他 | 罕见癌症

European Union Joint Action on Rare Cancers

2019年 发布于 Dig Liver Dis 51卷 第9期 所属人体系统： 消化 | 胃肠道肿瘤

2019年 发布于 Clin Ther 41卷 第11期 所属人体系统： 其他 | 康复营养

Turkey Medical Oncology Active Nutrition Platform

2018年 发布于 Strahlenther Onkol 194卷 第1期 所属人体系统： 泌尿 | 肾癌

无

2018年 所属人体系统： 运动 | 软组织肿瘤

McMaster University

共搜索到12条与GIST有关的结果

2021年发布于 Current Oncology 28卷第2期 所属人体系统：其他 | 腹膜肿瘤

2021年发布于 National Comprehensive Cancer Network 卷第期 所属人体系统：消化 | 胃肠道肿瘤

2021年发布于 Current Oncology 28卷第2期 所属人体系统：生殖 | 输卵管癌

2021年发布于 Current Oncology 28卷第2期 所属人体系统：生殖 | 卵巢肿瘤

2020年发布于 ESMO Open 5卷第2期 所属人体系统：其他 | 罕见癌症

2020年发布于 European Radiology 30卷第10期 所属人体系统：生殖 | 前列腺肿瘤

2019年发布于 Curr Oncol 26卷第2期 所属人体系统：其他 | 基因测序

2019年发布于 Eur J Cancer 110卷第期 所属人体系统：其他 | 罕见癌症

2019年发布于 Dig Liver Dis 51卷第9期 所属人体系统：消化 | 胃肠道肿瘤

2019年发布于 Clin Ther 41卷第11期 所属人体系统：其他 | 康复营养

2018年发布于 Strahlenther Onkol 194卷第1期 所属人体系统：泌尿 | 肾癌

2018年 所属人体系统：运动 | 软组织肿瘤